A Phase 3, Randomized, Open-Label Study To Evaluate the Efficacy and Safety of Eflornithine with Lomustine Compared to Lomustine Alone in Patients with Anaplastic Astrocytoma That Progress/Recur After Irradiation and Adjuvant Temozolomide Chemotherapy

Grants and Contracts Details

StatusActive
Effective start/end date9/1/163/20/23

Funding

  • Orbus Therapeutics Incorporated: $48,563.00